254
Views
11
CrossRef citations to date
0
Altmetric
Brief Report

Dehydroepiandrosterone in women with premature ovarian failure and Hashimoto's thyroiditis

, , , , , & show all
Pages 92-96 | Received 04 Feb 2013, Accepted 13 Apr 2013, Published online: 28 Jun 2013
 

Abstract

We evaluated dehydroepiandrosterone sulfate (DHEAS) levels in premature ovarian failure (POF) patients with and without Hashimoto's thyroiditis, and the impact of DHEA supplementation on thyroid autoantibodies. In a retrospective case series, we included 67 women with spontaneous POF who received estrogen/gestagen replacement with or without DHEA (30 mg/day) for 3 months. Women who were seropositive for thyroglobulin antibodies and/or thyroperoxidase autoantibodies (n = 30) revealed lower pretherapeutic DHEAS levels (1.2 μg/ml, range 0.4–2.9 μg/ml vs. 1.9 μg/ml, range 0.2–3.9 μg/ml; p < 0.001). DHEAS showed an inverse correlation with both thyroglobulin antibodies (r = −0.426, p < 0.001) and thyroperoxidase autoantibodies (r = −0.362, p = 0.002). When treated with additional DHEA, significant decreases were found for thyroperoxidase autoantibodies (median 85.0 IU/ml, range 41–600 IU/ml vs. median 51.0 IU/ml, range 20–589 IU/ml; p = 0.005) but not for thyroglobulin antibodies.

Conflict of interest The authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper.

Source of funding Nil.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.